| MARINOMED BIOTECHNOLOGIE GMBH Patent applications |
| Patent application number | Title | Published |
|---|
| 20120058206 | ANTIALLERGIC MARINE BIOPOLYMERS - The present invention relates to pharmaceutical compositions for administration to the respiratory tract, the gastrointestinal tract or the eyes. In particular, the invention relates to liquid formulations and dry powder compositions comprising carrageenan, and in particular iota and kappa carrageenan, and one or more therapeutic agents. These sprays, powders, and the gel that forms when they are administered to the respiratory tract, the gastrointestinal tract or the eyes, have now surprisingly been found to be a very effective way of prevention and treatment of type I allergies and intranasal administration of therapeutic agents. | 03-08-2012 |
| 20110224160 | Use of Escin for Treatment of Type IV Hypersensitivity Reaction - The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment of a Type IV hypersensitivity reaction or symptoms of a Type IV hypersensitivity reaction, such as in contact dermatitis, atopic dermatitis, hypersensitivity pneumonitis, chronic transplant rejection, graft versus host disease, cell mediated autoimmune diseases, Hashimoto's thyroiditis, Sjogren's disease, adrenalitis, polymyositis, or pernicious anemia. | 09-15-2011 |
| 20110091583 | ANTIALLERGIC MARINE BIOPOLYMERS - The present invention relates to pharmaceutical compositions based on carrageenan as an active ingredient, for use as a medicament in the prophylactic or therapeutic treatment of allergic conditions or diseases, with the proviso that the carrageenan comprises iota- and/or kappa-carrageenan and is substantially free of lambda carrageenan. Typically, the invention relates to liquid formulations, gels and dry powder compositions comprising iota- and/or kappa-carrageenan and, optionally, one or more non-carrageenan therapeutic agents for administration to the respiratory tract, the gastrointestinal tract or the eyes. The compositions of the invention have been found to be efficacious in the prevention and treatment of type I allergies and additionally, may exert an adjuvant function upon combined mucosal administration with non-carrageenan therapeutic agents. | 04-21-2011 |
| 20110059919 | ANTIVIRAL COMPOSITION COMPRISING A SULFATED POLYSACCHARIDE - The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus. | 03-10-2011 |
| 20100227830 | USE OF ESCIN - The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock. | 09-09-2010 |
| 20100160254 | Cellulose Sulfate for the Treatment of Rhinovirus Infection - The present invention provides the use of a polymer for the manufacture of an antiviral pharmaceutical composition for the treatment of a rhinovirus infection, wherein the polymer is cellulose sulfate. | 06-24-2010 |
| 20100040658 | ANTIVIRAL COMPOSITION AND METHOD OF USE - A method for manufacturing an antiviral pharmaceutical composition for the prophylaxis or treatment of a rhinovirus infection that includes the utilization of iota-, kappa- or lambda-carrageenan or mixtures thereof. | 02-18-2010 |
| 20090298792 | Anti-Inflammatory Polymer - The present invention provides the use of cellulose sulfate or chitosan for the manufacture of an anti-inflammatory pharmaceutical or cosmetic composition for the treatment of inflammation. | 12-03-2009 |
